Andrés López-Cortés, Santiago Guerrero, Esteban Ortiz-Prado, Verónica Yumiceba, Antonella Vera-Guapi, Ángela León Cáceres, Katherine Simbaña-Rivera, Ana María Gómez-Jaramillo, Gabriela Echeverría-Garcés, Jennyfer M García-Cárdenas, Patricia Guevara-Ramírez, Alejandro Cabrera-Andrade, Lourdes Puig San Andrés, Doménica Cevallos-Robalino, Jhommara Bautista, Isaac Armendáriz-Castillo, Andy Pérez-Villa, Andrea Abad-Sojos, María José Ramos-Medina, Ariana León-Sosa, Estefanía Abarca, Álvaro A Pérez-Meza, Karol Nieto-Jaramillo, Andrea V Jácome, Andrea Morillo, Fernanda Arias-Erazo, Luis Fuenmayor-González, Luis Abel Quiñones, Nikolaos C Kyriakidis
Background: It is imperative to identify drugs that allow treating symptoms of severe COVID-19. Respiratory failure is the main cause of death in severe COVID-19 patients, and the host inflammatory response at the lungs remains poorly understood. Methods: Therefore, we retrieved data from post-mortem lungs from COVID-19 patients and performed in-depth in silico analyses of single-nucleus RNA sequencing data, inflammatory protein interactome network, and shortest pathways to physiological phenotypes to reveal potential therapeutic targets and drugs in advanced-stage COVID-19 clinical trials...
2022: Frontiers in Pharmacology